Procedure for predicting progressing hepatic fibrosis in patients with human immunodeficiency and hepatitis C coinfection

View or download the full article: 
PDF icon health-risk-analysis-2020-2-16.pdf
UDC: 
616-099
DOI: 
10.21668/health.risk/2020.2.16.eng
Authors: 

V.V. Maslyakov, M.S. Aristanbekova

Organization: 

«Reaviz» Medical University, 227 Chapaevskaya Str., Samara, 443001, Russian Federation

Abstract: 

Our research goal was to develop a system for predicting nature of fibrosis processes in patients infected with HIV and Hepatitis C virus and to assess its efficiency bearing in mind peculiarities of anti-virus therapy applied for treating the infections.
Research was performed on 459 patients with confirmed HIV/viral hepatitis C who had been treated for 1 year at Saratov Regional Center for AIDS Prevention and Elimination. Most patients were males younger than 36. 72–78% patients had 3–4A HIV infection stages. The rest had 4B–C stages. 32% were treated only with sets of anti-retroviruses medications made up of nucleoside and non-nucleoside inhibitors of reverse transcriptase, inhibitors of protease, and inhibitors of integrase in different combinations. 14% patients infected with both HIV and Hepatitis C virus were treated only with antiviral medications aimed for treating hepatitis C and made up of pegylated interferon α and ribavirin or medications with direct effects such as sofosbuvir and daclatasvir. 19% patients were prescribed both antiviral therapy aimed at treating Hepatitis C and anti-retrovirus therapy.
Research results allowed establishing risk criteria for progressing hepatic fibrosis; they included fibro scanning of liver, number of CD3+CD4+ cells in blood, and immune regulatory index. Basing on the research data, we created an integral parameter for assessing quantitative risk criteria that could be used when a patient was examined for the first time or during a short-term observation period.

Keywords: 
HIV/Hepatitis C co-infection, infection process, progressing hepatic fibrosis, fibro scanning, Т-lymphocytes subpopulations, antiviral therapy, high risk index, risk criteria
Maslyakov V.V., Aristanbekova M.S. Procedure for predicting progressing hepatic fibrosis in patients with human immunodeficiency and hepatitis C coinfection. Health Risk Analysis, 2020, no. 2, pp. 143–151. DOI: 10.21668/health.risk/2020.2.16.eng
References: 
  1. Scott J.A., Chew K.W. Treatment optimization for HIV/HCV co-infected patients. Ther Adv Infect Dis, 2017, vol. 4, no. 1, pp. 18–36. DOI: 10.1177/2049936116681279
  2. Nunez M., Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Safety, 2005, vol. 28, no. 1, pp. 53–66. DOI: 10.2165/00002018-200528010-00004
  3. Shostakovich-Korets'ka L.R., Shevchenko-Makarenko O.P., Chukhalova I.V., Nosenko O.V. Monitoring of therapy in patients with HIV/HCV co-infection who receive antiviral therapy against hepatitis C and antiretroviral therapy. Aktual'naya infektologiya, 2017, vol. 5, no. 7, pp. 290–292 (in Russian).
  4. Soriano V., Labarga P., Fernandez-Montero J.V. Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opin Drug Metab Toxicol, 2017, vol. 13, no. 8, pp. 807–816. DOI: 10.1080/17425255.2017.1351942
  5. Rockstroh J.K. Management of hepatitis C/HIV co-infection. Curr Opin Infect Dis, 2006, vol. 19, no. 1, pp. 8–13. DOI: 10.1097/01.qco.0000200294.22661.e0
  6. Aubinskaya G.M., Koval' T.I., Sizova L.M., Rudenko S.S., Limarenko N.P. Optimizatsiya prognozirovaniya tempa progressirovaniya fibroza pecheni u VICh-infitsirovannykh patsientov s khronicheskim gepatitom C [Optimizing prediction of hepatic fibrosis progress rate in patients infected with HIV and suffering from chronic Hepatitis C. Aktual'naya infektologiya, 2018, vol. 6, no. 5, pp. 258–259 (in Russian).
  7. Sobyanina S.N., Yurganova G.A. Substantiation and evaluation of using of peg-modified interferons combined with darunavir for treating of chronic HCV and HIV-infections. VICh-infektsiya i immunosupressii, 2010, vol. 2, no. 3, pp. 118–122 (in Russian).
  8. Chen T.Y., Ding E.L., Seage Iii G.R., Kim A.Y. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis, 2009, vol. 49, no. 10, pp. 1605–1615. DOI: 10.1086/644771
  9. Znoiko O.O. Hard-to-treat patient with hepatitis C – what will change with interferon-free therapy? Infektsionnye bolezni: novosti, mneniya, obuchenie, 2014, no. 2, pp. 60–67 (in Russian).
  10. Del Bello D., Ita Nagy F., Hand J. Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients. J Curr Opin HIV AIDS, 2015, vol. 10, no. 5, pp. 337–347. DOI: 10.1097/COH.0000000000000182
  11. Pavlov D.V., Shatrova D.Kh., Galiullin N.I., Nagimova F.I. Peculiarities of HIV-positive patients co-infection with hepatitis C virus. Kazanskii meditsinskii zhurnal, 2014, vol. 95, no. 6, pp. 905–908 (in Russian).
  12. Kravchenko A.V., Kanestri V.G., Kuimova U.A. Modern recommendations for using hepatitis C virus protease inhibitors in patients with combined infection (HIV infection/chronic hepatitis C). Infektsionnye bolezni, 2012, no. 3, pp. 90–95 (in Russian).
  13. Mena A., Meijide H., Rodríguez-Osorio I. Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus co-infection in persons living with HIV. HIV Med, 2017, vol. 18, no. 9, pp. 685–689. DOI: 10.1111/hiv.12502
  14. Kravchenko A.V., Aksenova V.A., Gurkina L.A. The HIV integrase inhibitor raltegravir as part of antiretroviral therapy schemes in patients with HIV infection and hepatitis. Infektsionnye bolezni, 2015, no. 3, pp. 5–11 (in Russian).
  15. Kaur K., Gandhi M.A., Slish J. Drug-Drug Interactions among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications. Infect Dis Ther, 2015, vol. 4, no. 2, pp. 159–172. DOI: 10.1007/s40121-015-0061-2
  16. Manapova E.R., Fazylov V.Kh., Beshimov A.T. Efficacy of antiviral treatment of chronic hepatitis C in patients with HCV/HIV co-infection in the comparative aspect. Infektsionnye bolezni: novosti, mneniya, obuchenie, 2017, no. 4 (21), pp. 51–56 (in Russian).
  17. Yuschuk N.D., Maximov S.L., Ivanov L.M., Klimova Ye.A., Znoyko O.O., Kravchenko A.V. The combined therapy of chronic hepatitis with pegilated interferon α-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii, 2009, vol. 19, no. 1, pp. 35–42 (in Russian).
  18. Yushchuk N.D., Klimova E.A., Znoiko O.O., Karetkina G.N., Maksimov S.L., Martynov Yu.V., Shukhov V.S., Dudina K.R. [et al.]. Protokol diagnostiki i lecheniya bol'nykh virusnymi gepatitami B i C [The Procedure for diagnostics and treatment of patients with virus hepatitis B and C]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii, 2010, vol. 20, no. 6, pp. 4–60 (in Russian).
  19. Kanestri V.G., Kravchenko A.V., Gankina N.Yu. Hepatotoxicity of antiretroviral therapy in HIV-infected patients. Epidemiologiya i infektsionnye bolezni. Aktual'nye voprosy, 2014, no. 1, pp. 31–36 (in Russian).
  20. Azovtseva O.V., Arkhipova E.I., Arkhipov G.S. Clinical and genotypic features of co-infection with hepatitis C virus and HIV. VICh-infektsiya i immunosupressii, 2010, vol. 2, no. 2, pp. 42–47 (in Russian).
Received: 
18.07.2019
Accepted: 
13.06.2020
Published: 
30.06.2020

You are here

Home